We demonstrate that the induced migration of a2Neuɸ is hampered significantly by anti-IL-8 neutralizing monoclonal antibody as well as by reparixin; a CXCR-1 and CXCR-2 inhibitor that is used in phase 2 clinical trial for Triple negative breast cancer treatment50. Here, CXCR1 is linked to breast cancer.